Highest-materiality recent filing
Ham Jung Kyu resigned from board effective June 30, 2026; no disagreement with company.
Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained
Received Nasdaq delinquency notice on May 28, 2026 for late Q1 2026 10-Q filing.
Exicure appoints Yoontae Han as director, Dongho Lee as Audit Chair, Young Seung Ko as COO
Yoontae Han appointed director and Audit Committee member effective April 8, 2026; $20,000 annual retainer.
Exicure derivative settlement preliminarily approved; includes governance reforms and $675k fee
Court preliminarily approved settlement on March 19, 2026; final hearing set for June 2, 2026.
Exicure director Sangjin Yeo resigns from Board and Audit Committee effective March 27, 2026
Sangjin Yeo submitted resignation on March 25, 2026, effective March 27, 2026.
Exicure FY2025 net loss $4.9M; cash $3.7M; warns cash insufficient for 12 months
Cash and cash equivalents $3.7M as of Dec 31 2025, down from $12.5M a year ago.
Exicure appoints Jung Soo Kim as CEO and Gyuyeob Lee as interim CFO
CEO Andy Yoo and CFO Seung Ik Baik resigned effective Feb 9, 2026.
Exicure CEO Andy Yoo, CFO Seung Ik Baik resign; three new directors appointed
Andy Yoo resigned as CEO/President and Seung Ik Baik as CFO/Secretary, effective Feb 9, 2026; no successors named.
Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics
Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.
Exicure redeems 4.5B KRW (~$3.125M) in convertible bonds from subsidiary KC Creation
Redeemed 4.5B KRW ($3.125M) of 2.90% Convertible Bonds due 2028 issued by wholly-owned subsidiary KC Creation.
Sangjin Yeo and Aejin Hwang elected Class II directors with 3,481,839 votes each; no withhold votes.
Exicure Q3 net loss widens to $2.4M; cash burn and going concern warning
Cash and cash equivalents fell to $4.4M at Sep 30, 2025 from $12.5M at Dec 31, 2024.
Exicure appoints two new directors; four directors resign effective Sept 8, 2025
Appointed Sangjn Yeo and Aejin Hwang to the Board as Class II directors; Yeo appointed Chairman of audit committee.
Exicure reports Q2 net loss of $2.6M; warns going concern, needs financing
Cash and equivalents fell to $7.9M at June 30, 2025, from $12.5M at Dec 31, 2024.
Exicure regains compliance with Nasdaq periodic filing requirement
As of July 1, 2025, Exicure regained compliance with Nasdaq Listing Rule 5250(c)(1).
Exicure reports Q1 net income of $3.0M on lease gain; warns cash insufficient for operations
Cash and equivalents $10.4M (Dec 2024: $12.5M); net income $3.0M vs loss $0.8M YoY.
Exicure raises CEO salary to $480K, CFO to $300K; CEO gets 24-month severance
CEO Andy Yoo salary increased to $480,000; CFO Seung Ik Baik salary increased to $300,000.
Exicure receives Nasdaq delinquency notice for late Q1 2025 Form 10-Q filing
Received Nasdaq delinquency notice on May 21, 2025 for failure to timely file Form 10-Q for quarter ended March 31, 2025.
Exicure invests ~$3.125M in convertible bonds of wholly-owned subsidiary KC Creation
Subscription amount of KRW 4.5B (≈$3.125M) for non-guaranteed private placement convertible bonds.
Marcum resigned as independent auditor on April 10, 2025; CBIZ CPAs engaged immediately for 2025.
Exicure reports FY2024 net loss of $9.7M, cash $12.5M, going concern warning
Cash and cash equivalents $12.5M as of Dec 31, 2024, up from $0.8M year-end 2023; management warns liquidity may not last 12 months.
Exicure board members Jiyoung Hwang and Paul Kang resign; Kang to provide consulting for 12 months
Jiyoung Hwang resigned from the Board on Feb 28, 2025 for personal reasons; no disagreement.
Exicure raises ~$2M in stock sale to two investors; records $6M lease-termination gain
Raised ~$2M via sale of 290,908 shares at $5.50 each to Shin Chang Partners and RMS0718 Co., Ltd.
Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement
Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.
Exicure buys GPCR USA for ~$1.62M; milestone & royalty deal with GPCR Therapeutics
Acquired all outstanding shares of GPCR Therapeutics USA from GPCR Therapeutics for ~$0.27/share (total ~$1.62M).
Exicure receives $8.7M from HiTron, appoints audit committee members
Received $8.7M on Dec 24, 2024 from closing of Common Stock Purchase Agreement with HiTron Systems Inc.
Exicure shareholders approve $8.7M HiTron investment; CEO and board changes; Nasdaq plan presented
Shareholders approved $8.7M second investment from HiTron; total HiTron investment $10M at $3/share.
On Dec 20, 2024, Nasdaq confirmed Exicure meets all requirements for continued listing as of Dec 17, 2024.
Exicure shareholders approve $8.7M HiTron investment; change of control, new CEO and board
Shareholders approved 2.9M shares to HiTron at $3/share for $8.7M second investment, totaling $10M; HiTron holds >50%.
Exicure raises $12M via stock sales to regain Nasdaq equity compliance; pro forma equity ~$4.3M
Sold 433K shares to HiTron Systems at $3/share for $1.3M net proceeds on Nov 21, 2024.
Exicure to issue 433,332 shares at $4.61 for $2M gross proceeds to SangSangIn
Common Stock Purchase Agreement with SangSangIn Investment & Securities Co., Ltd.
Exicure appoints new board members and CRO; receives $1.3M from HiTron deal closing
Andy Yoo appointed as Class I director and Chief Restructuring Officer; Seung Ik Baik as Class III director effective Nov 21, 2024.
Exicure gets Nasdaq extension to Dec 17; delisting risk persists
Nasdaq Hearings Panel granted extension to December 17, 2024, for listing compliance.
Exicure announces $10M equity financing from HiTron, Q3 net loss $1.1M, cash $0.3M
Initial sale of 433,333 shares at $3.00/share to HiTron for $1.3M; closing expected within 10 days.
Exicure sells core SNA technology to Flashpoint for $1.5M; appoints new director
Sold spherical nucleic acid technology, R&D programs, and clinical assets to Flashpoint Therapeutics for $1.5 million gross proceeds.
Nasdaq Panel grants Exicure listing extension until Nov 14, 2024; debt-to-equity swap completed
Extension granted on Sept 17, 2024; must evidence compliance with all continued listing criteria by Nov 14, 2024.
Exicure converts $1M debt to equity at $3/share; regains Nasdaq compliance
Converted $700K promissory note from DGP Co., Ltd. into 237,233 shares at $3.00/share.
Exicure announces 1-for-5 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1-for-5 ratio effective 5:00 pm ET Aug 27, 2024; trading on split-adjusted basis from Aug 28.
Exicure special meeting adjourned again to Aug 20; only 49.7% shares voted
Special meeting adjourned from Aug 19 to Aug 20, 2024 at 9:00 AM CT due to lack of quorum.
Exicure special meeting adjourned; quorum not reached at 49.4% votes
Special meeting on Aug 15 adjourned due to lack of quorum; only 49.4% of outstanding shares voted.
Exicure Q2 2024 net loss $0.6M; cash only $0.5M, warns of insufficient funding and going concern
Cash and cash equivalents $0.5M at June 30, 2024, down from $0.8M at Dec 31, 2023.
Exicure gets Nasdaq continued listing with Sept. 16 compliance deadline
Nasdaq Hearings Panel determined to continue Exicure's listing subject to evidencing compliance by September 16, 2024.
Elected Class III directors Paul Kang (4,389,180 for) and Hyuk Joon Ko (4,381,669 for); Class I directors Jiyoung Hwang (4,290,978 for) and Dongho Lee (4,381,699 for).
Exicure receives Nasdaq delisting notice for minimum equity failure
Received Nasdaq delinquency notice on June 20, 2024 for non-compliance with minimum $2.5M stockholders' equity requirement.
Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern
Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.
Cash and cash equivalents fell to $0.8M at Dec 2023 and further to ~$0.2M by May 31, 2024.
Nasdaq notified Exicure on May 21 of delisting; trading suspension effective May 30 unless appeal by May 28.
Exicure cash drops to $0.2M; warns going concern, needs funding imminently
Cash and equivalents fell from $8.6M (Dec 31, 2022) to $0.9M (Sep 30, 2023); further to ~$0.2M by Apr 30, 2024.
Exicure receives Nasdaq delinquency notice for late 10-K; must comply by May 20, 2024
On April 17, 2024, Nasdaq notified Exicure of non-compliance for failing to file its 2023 Form 10-K (Rule 5250(c)(1)).
Exicure licenses cavrotolimod patents to Bluejay for hepatitis treatment
Bluejay receives exclusive license in hepatitis field to Exicure's patents; small upfront payment made.
To fill the newly created directorship resulting from the increase in the size of the Board, the Board appointed Han Eui Seok to serve as a Class III director of the Company, effective as of June 30, 2026.
On June 24, 2026, Ham Jung Kyu resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”), effective as of June 30, 2026.
To fill the vacancy created by the resignation of Ham Jung Kyu, the Board appointed Go Jin Young to serve as a Class III director of the Company, effective as of June 30, 2026.
In conjunction with the execution of this consulting agreement, Mr. Kang resigned from the Board for personal reasons, effective as of March 3, 2025.
On February 28, 2025, Jiyoung Hwang resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”) for personal reasons, effective immediately as of such date.
the Company announced the appointment of Chang Keun Choi and Minwoo Kang to the Company's Board of Directors (the 'Board'), effective December 19, 2024.
the Company announced the appointment of Chang Keun Choi and Minwoo Kang to the Company's Board of Directors (the 'Board'), effective December 19, 2024.
effective January 1, 2005, Mr. Choi and Mr. Kang have been appointed to the Audit Committee of the Board, with Mr. Kang serving as the Chair of the Audit Committee.
on November 21, 2024, the Board of Directors (the "Board’) of the Company appointed Andy Yoo and Seung Ik Baik to the Board.
on November 21, 2024, the Board of Directors (the "Board’) of the Company appointed Andy Yoo and Seung Ik Baik to the Board.
On November 21, 2024, Eui Yull Hwang resigned from the Board for personal reasons, effective immediately as of such date.
On November 21, 2024, Hojoon Lee resigned from the Board for personal reasons, effective immediately as of such date.
Max materiality 1.00 · Median 0.68 · Most common event other_material